MedTrace Logo

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

NCT01030640 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-04-26

No results posted yet for this study

Summary

Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.

Conditions

  • Osteoarthritis Pain
  • Chronic Low Back Pain
  • Pain Due to Interstitial Cystitis

Interventions

OTHER

placebo

single dose of the drug formulation

BIOLOGICAL

tanezumab

single dose of the active drug tanezumab at a dose level of 20 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01030640 on ClinicalTrials.gov